These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 9327249

  • 1. Serum inhibitory titers and serum bactericidal titers for human subjects receiving multiple doses of the antibacterial oxazolidinones eperezolid and linezolid.
    Schaadt RD, Batts DH, Daley-Yates PT, Pawsey SD, Stalker DJ, Zurenko GE.
    Diagn Microbiol Infect Dis; 1997 Aug; 28(4):201-4. PubMed ID: 9327249
    [Abstract] [Full Text] [Related]

  • 2. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.
    Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW.
    Antimicrob Agents Chemother; 1998 Mar; 42(3):721-4. PubMed ID: 9517963
    [Abstract] [Full Text] [Related]

  • 3. Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium.
    Schülin T, Thauvin-Eliopoulos C, Moellering RC, Eliopoulos GM.
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2873-6. PubMed ID: 10582874
    [Abstract] [Full Text] [Related]

  • 4. Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations.
    Brauers J, Kresken M, Menke A, Orland A, Weiher H, Morrissey I.
    Int J Antimicrob Agents; 2007 Mar; 29(3):322-5. PubMed ID: 17204403
    [Abstract] [Full Text] [Related]

  • 5. In vitro activity of linezolid against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.
    Patel R, Rouse MS, Piper KE, Steckelberg JM.
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):119-22. PubMed ID: 10354862
    [Abstract] [Full Text] [Related]

  • 6. Piperazinyl oxazolidinone antibacterial agents containing a pyridine, diazene, or triazene heteroaromatic ring.
    Tucker JA, Allwine DA, Grega KC, Barbachyn MR, Klock JL, Adamski JL, Brickner SJ, Hutchinson DK, Ford CW, Zurenko GE, Conradi RA, Burton PS, Jensen RM.
    J Med Chem; 1998 Sep 10; 41(19):3727-35. PubMed ID: 9733498
    [Abstract] [Full Text] [Related]

  • 7. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections.
    Ford CW, Hamel JC, Wilson DM, Moerman JK, Stapert D, Yancey RJ, Hutchinson DK, Barbachyn MR, Brickner SJ.
    Antimicrob Agents Chemother; 1996 Jun 10; 40(6):1508-13. PubMed ID: 8726028
    [Abstract] [Full Text] [Related]

  • 8. Inoculum effects of ceftobiprole, daptomycin, linezolid, and vancomycin with Staphylococcus aureus and Streptococcus pneumoniae at inocula of 10(5) and 10(7) CFU injected into opposite thighs of neutropenic mice.
    Lee DG, Murakami Y, Andes DR, Craig WA.
    Antimicrob Agents Chemother; 2013 Mar 10; 57(3):1434-41. PubMed ID: 23295932
    [Abstract] [Full Text] [Related]

  • 9. In vivo pharmacodynamics of a new oxazolidinone (linezolid).
    Andes D, van Ogtrop ML, Peng J, Craig WA.
    Antimicrob Agents Chemother; 2002 Nov 10; 46(11):3484-9. PubMed ID: 12384354
    [Abstract] [Full Text] [Related]

  • 10. Susceptibility testing of linezolid by two standard methods.
    Hamilton-Miller JM, Shah S.
    Eur J Clin Microbiol Infect Dis; 1999 Mar 10; 18(3):225-7. PubMed ID: 10357061
    [Abstract] [Full Text] [Related]

  • 11. In vitro activities of the oxazolidinone compounds linezolid (PNU-100766) and eperzolid (PNU-100592) against middle ear isolates of Streptococcus pneumoniae.
    Kearney JA, Barbadora K, Mason EO, Wald ER, Green M.
    Int J Antimicrob Agents; 1999 Jul 10; 12(2):141-4. PubMed ID: 10418759
    [Abstract] [Full Text] [Related]

  • 12. Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009.
    Dowzicky MJ.
    Clin Ther; 2011 Dec 10; 33(12):1964-73. PubMed ID: 22078154
    [Abstract] [Full Text] [Related]

  • 13. In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.
    Sweeney MT, Zurenko GE.
    Antimicrob Agents Chemother; 2003 Jun 10; 47(6):1902-6. PubMed ID: 12760865
    [Abstract] [Full Text] [Related]

  • 14. Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.
    Ba BB, Arpin C, Bikie Bi Nso B, Dubois V, Saux MC, Quentin C.
    Antimicrob Agents Chemother; 2010 Apr 10; 54(4):1443-52. PubMed ID: 20100878
    [Abstract] [Full Text] [Related]

  • 15. Post-antibiotic growth suppression of linezolid against Gram-positive bacteria.
    Munckhof WJ, Giles C, Turnidge JD.
    J Antimicrob Chemother; 2001 Jun 10; 47(6):879-83. PubMed ID: 11389123
    [Abstract] [Full Text] [Related]

  • 16. Global in vitro activity of tigecycline and linezolid against Gram-positive organisms collected between 2004 and 2009.
    Dowzicky MJ, Chmelařová E.
    Int J Antimicrob Agents; 2011 Jun 10; 37(6):562-6. PubMed ID: 21497066
    [Abstract] [Full Text] [Related]

  • 17. Linezolid: a review of its use in the management of serious gram-positive infections.
    Perry CM, Jarvis B.
    Drugs; 2001 Jun 10; 61(4):525-51. PubMed ID: 11324682
    [Abstract] [Full Text] [Related]

  • 18. Impact of Enterococcus faecalis on the bactericidal activities of arbekacin, daptomycin, linezolid, and tigecycline against methicillin-resistant Staphylococcus aureus in a mixed-pathogen pharmacodynamic model.
    LaPlante KL, Rybak MJ, Leuthner KD, Chin JN.
    Antimicrob Agents Chemother; 2006 Apr 10; 50(4):1298-303. PubMed ID: 16569844
    [Abstract] [Full Text] [Related]

  • 19. Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae.
    Isaacson G, Aronoff SC.
    Int J Pediatr Otorhinolaryngol; 2008 May 10; 72(5):647-51. PubMed ID: 18321598
    [Abstract] [Full Text] [Related]

  • 20. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
    McKay GA, Beaulieu S, Arhin FF, Belley A, Sarmiento I, Parr T, Moeck G.
    J Antimicrob Chemother; 2009 Jun 10; 63(6):1191-9. PubMed ID: 19369269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.